الفهرس Only 14 pages are availabe for public view
 |  | from | 153 |  |  |
| | | from | 153 | | |
Abstract
Breast cancer is first malignant tumor affecting females,contributing 30% of all female cancers. In Egypt breast cancer constitutes 33% of all female cancers in Egyptian national cancer institute.
Hormonal treatment in hormonal responsive breast cancer is associated with reduction in the recurrence rate and mortality rate in women with breast cancer.
Tamoxifen has been the golden standard adjuvant hormonal therapy in postmenopausal women. Recently the introduction of aromatase inhibitors was associated with improvement of the DFS, lower local and distant relapse rates and less serious complications. So that aromatase inhibitors became a strong and attractive alternative to tamoxifen in postmenopausal women with hormone responsive breast cancer.
A major problem facing the oncologists with the introduction of new treatment lines like aromatase inhibitors and targeted molecular therapy is the high costs of these treatments, and if the benefits from these treatments worth this high cost or not.
Cost-effectiveness analysis compares the cost of the intervention with the effect, resulting in a cost per effect (e.g. cost per year of life gained) that can be compared across interventions.
Most of CEA studies have been conducted in Europe, North America and Australia. This type of economic studies has less interest between physicians in spite of its great importance in decision making.
In our thesis we tried to assess the ICER of letozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer in Egypt.
The results of our thesis are in accordance with those conducted in Europe and North America, that letozole is cost-effective in comparison to tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer.